Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JinRui Foundation
Chengdu, Sichuan, China
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
JinRui Foundation develops innovative and first-in-class therapies, with several programs in Phase 2 targeting tumor and neurological indications. Notably, XH-6003 (NKCC1 x NKCC2, for cerebral hemorrhage) and Honokiol Liposome (FOXM1, for glioblastoma multiforme) have reached Phase 2 clinical development. The company benchmarks its R&D pipeline against multinational pharmaceutical companies with strong preclinical and early clinical-stage assets.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small moleculeHerbal medicineChemical drugsLiposomal drug
- Industry
- Biotech
02
Partnerships
State Key Laboratory of Biotherapy of Sichuan Universitymany external world-class teams
Beyond the preview
Go deeper on JinRui Foundation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JinRui Foundation.